Karyopharm Therapeutics (KPTI) Other Non-Current Liabilities (2014 - 2025)

Karyopharm Therapeutics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $72.3 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities rose 2876.87% year-over-year to $72.3 million; the trailing twelve-month figure through Dec 2025 stood at $72.3 million (up 2876.87% YoY), and the FY2025 full-year result was $72.3 million, up 2876.87% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $72.3 million, up from $14.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $133.0 million in Q4 2021, with the low at $1.1 million in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $83.5 million across 5 years, with a median of $73.5 million in 2024.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 99.18% — and 2025, when it jumped 2876.87%.
• Karyopharm Therapeutics' Other Non-Current Liabilities stood at $133.0 million in 2021, then changed by 0.0% to $133.0 million in 2022, then declined by 0.39% to $132.5 million in 2023, then sank by 98.17% to $2.4 million in 2024, then jumped by 2876.87% to $72.3 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $72.3 million (Q4 2025), $14.1 million (Q3 2025), and $73.5 million (Q2 2025), per Business Quant data.